Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-XT033 in Metastatic Prostate Cancer
NCT06081686Phase 2Recruiting
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium Lu-177 XT033 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Sinotau Pharmaceutical Group. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 2 years, Whole body and organ uptake of [177Lu]Lu-XT033 Injection up to 12 months and 4 more. Started Sep 2023; status: recruiting.
02
Drugs
lutetium Lu-177 XT033
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06081686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081686.